Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 435


Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy.

Rendo V, Stoimenov I, Mateus A, Sjöberg E, Svensson R, Gustavsson AL, Johansson L, Ng A, OʼBrien C, Giannakis M, Artursson P, Nygren P, Cheong I, Sjöblom T.

Nat Commun. 2020 Mar 11;11(1):1308. doi: 10.1038/s41467-020-15111-4.


TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).

Hammel P, Feliu J, Parner V, Berardi R, Van Cutsem E, Greil R, Wasan H, Metges J, Nygren P, Osterlund P, Seufferlein T, Creemers G, Biswas-Baldwin N, Youssoufian H, Gupta A, Salesse S, Dion H, El-Hariry I, Hidalgo M.

Ann Oncol. 2019 Jul;30 Suppl 4:iv26. doi: 10.1093/annonc/mdz155.097. Epub 2019 Dec 4. No abstract available.


Effects of a nutrition intervention on acute and late bowel symptoms and health-related quality of life up to 24 months post radiotherapy in patients with prostate cancer: a multicentre randomised controlled trial.

Forslund M, Ottenblad A, Ginman C, Johansson S, Nygren P, Johansson B.

Support Care Cancer. 2019 Nov 22. doi: 10.1007/s00520-019-05182-5. [Epub ahead of print]


A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation.

Karlsson H, Senkowski W, Fryknäs M, Mansoori S, Linder S, Gullbo J, Larsson R, Nygren P.

Oncotarget. 2019 Sep 3;10(51):5372-5382. doi: 10.18632/oncotarget.27166. eCollection 2019 Sep 3.


Experiences of a nutrition intervention-A qualitative study within a randomised controlled trial in men undergoing radiotherapy for prostate cancer.

Forslund M, Nygren P, Ottenblad A, Johansson B.

Nutr Diet. 2019 Jun 27. doi: 10.1111/1747-0080.12564. [Epub ahead of print]


Percutaneous Irreversible Electroporation as First-line Treatment of Locally Advanced Pancreatic Cancer.

Månsson C, Brahmstaedt R, Nygren P, Nilsson A, Urdzik J, Karlson BM.

Anticancer Res. 2019 May;39(5):2509-2512. doi: 10.21873/anticanres.13371.


Which exercise prescriptions optimize V̇O2 max during cancer treatment?-A systematic review and meta-analysis.

Bjørke ACH, Sweegers MG, Buffart LM, Raastad T, Nygren P, Berntsen S.

Scand J Med Sci Sports. 2019 Sep;29(9):1274-1287. doi: 10.1111/sms.13442. Epub 2019 May 28.


Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition.

Blom K, Rubin J, Berglund M, Jarvius M, Lenhammar L, Parrow V, Andersson C, Loskog A, Fryknäs M, Nygren P, Larsson R.

BMC Res Notes. 2019 Apr 22;12(1):234. doi: 10.1186/s13104-019-4273-5.


Lysis of Staphylococcal Cells by Modular Lysin Domains Linked via a Non-covalent Barnase-Barstar Interaction Bridge.

Hjelm LC, Nilvebrant J, Nygren PÅ, Nilsson AS, Seijsing J.

Front Microbiol. 2019 Mar 22;10:558. doi: 10.3389/fmicb.2019.00558. eCollection 2019.


Lessons learned from the maturation of a cancer drug: oxaliplatin in colorectal cancer.

Glimelius B, Nygren P.

Acta Oncol. 2019 Apr;58(4):395-397. doi: 10.1080/0284186X.2019.1584405. Epub 2019 Mar 18. No abstract available.


Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin.

Hafstrand I, Sayitoglu EC, Apavaloaei A, Josey BJ, Sun R, Han X, Pellegrino S, Ozkazanc D, Potens R, Janssen L, Nilvebrant J, Nygren PÅ, Sandalova T, Springer S, Georgoudaki AM, Duru AD, Achour A.

Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5055-5060. doi: 10.1073/pnas.1807656116. Epub 2019 Feb 26.


Chromophore pre-maturation for improved speed and sensitivity of split-GFP monitoring of protein secretion.

Lundqvist M, Thalén N, Volk AL, Hansen HG, von Otter E, Nygren PÅ, Uhlen M, Rockberg J.

Sci Rep. 2019 Jan 22;9(1):310. doi: 10.1038/s41598-018-36559-x.


A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors.

Mody K, Mansfield AS, Vemireddy L, Nygren P, Gulbo J, Borad M.

Invest New Drugs. 2019 Aug;37(4):684-692. doi: 10.1007/s10637-018-0703-9. Epub 2018 Nov 21.


Single nucleotide polymorphisms alter kinase anchoring and the subcellular targeting of A-kinase anchoring proteins.

Smith FD, Omar MH, Nygren PJ, Soughayer J, Hoshi N, Lau HT, Snyder CG, Branon TC, Ghosh D, Langeberg LK, Ting AY, Santana LF, Ong SE, Navedo MF, Scott JD.

Proc Natl Acad Sci U S A. 2018 Dec 4;115(49):E11465-E11474. doi: 10.1073/pnas.1816614115. Epub 2018 Nov 19.


Pneumolysin binds to the mannose receptor C type 1 (MRC-1) leading to anti-inflammatory responses and enhanced pneumococcal survival.

Subramanian K, Neill DR, Malak HA, Spelmink L, Khandaker S, Dalla Libera Marchiori G, Dearing E, Kirby A, Yang M, Achour A, Nilvebrant J, Nygren PÅ, Plant L, Kadioglu A, Henriques-Normark B.

Nat Microbiol. 2019 Jan;4(1):62-70. doi: 10.1038/s41564-018-0280-x. Epub 2018 Nov 12.


Aggregatibacter actinomycetemcomitans leukotoxin causes activation of lymphocyte function-associated antigen 1.

Nygren P, Balashova N, Brown AC, Kieba I, Dhingra A, Boesze-Battaglia K, Lally ET.

Cell Microbiol. 2019 Mar;21(3):e12967. doi: 10.1111/cmi.12967. Epub 2018 Nov 28.


Correction to: What's Happening During Home Visits? Exploring the Relationship of Home Visiting Content and Dosage to Parenting Outcomes.

Nygren P, Green B, Winters K, Rockhill A.

Matern Child Health J. 2018 Oct;22(Suppl 1):120. doi: 10.1007/s10995-018-2627-6.


Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing.

Rubin J, Mansoori S, Blom K, Berglund M, Lenhammar L, Andersson C, Loskog A, Fryknäs M, Nygren P, Larsson R.

Oncotarget. 2018 Jul 20;9(56):30805-30813. doi: 10.18632/oncotarget.25713. eCollection 2018 Jul 20.


What's Happening During Home Visits? Exploring the Relationship of Home Visiting Content and Dosage to Parenting Outcomes.

Nygren P, Green B, Winters K, Rockhill A.

Matern Child Health J. 2018 Oct;22(Suppl 1):52-61. doi: 10.1007/s10995-018-2547-5. Erratum in: Matern Child Health J. 2018 Aug 22;:.


Site-Specific Photoconjugation of Beta-Lactamase Fragments to Monoclonal Antibodies Enables Sensitive Analyte Detection via Split-Enzyme Complementation.

Yu F, Alesand V, Nygren PÅ.

Biotechnol J. 2018 Jul;13(7):e1700688. doi: 10.1002/biot.201700688. Epub 2018 Mar 14.


Ex vivo activity of cytotoxic drugs and targeted agents in small intestinal neuroendocrine tumors.

Daskalakis K, Norlén O, Karakatsanis A, Hellman P, Larsson R, Nygren P, Stålberg P.

Endocr Relat Cancer. 2018 Apr;25(4):471-480. doi: 10.1530/ERC-17-0404. Epub 2018 Feb 12.


Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism.

Kashif M, Andersson C, Mansoori S, Larsson R, Nygren P, Gustafsson MG.

Oncotarget. 2017 Oct 19;8(61):103952-103967. doi: 10.18632/oncotarget.21895. eCollection 2017 Nov 28.


Targeting tumor cells based on Phosphodiesterase 3A expression.

Nazir M, Senkowski W, Nyberg F, Blom K, Edqvist PH, Jarvius M, Andersson C, Gustafsson MG, Nygren P, Larsson R, Fryknäs M.

Exp Cell Res. 2017 Dec 15;361(2):308-315. doi: 10.1016/j.yexcr.2017.10.032. Epub 2017 Oct 26.


Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.

Eriksson A, Chantzi E, Fryknäs M, Gullbo J, Nygren P, Gustafsson M, Höglund M, Larsson R.

Leuk Res. 2017 Dec;63:41-46. doi: 10.1016/j.leukres.2017.10.012. Epub 2017 Oct 28.


Melflufen - a peptidase-potentiated alkylating agent in clinical trials.

Wickström M, Nygren P, Larsson R, Harmenberg J, Lindberg J, Sjöberg P, Jerling M, Lehmann F, Richardson P, Anderson K, Chauhan D, Gullbo J.

Oncotarget. 2017 Jun 8;8(39):66641-66655. doi: 10.18632/oncotarget.18420. eCollection 2017 Sep 12. Review.


Intrinsic disorder within AKAP79 fine-tunes anchored phosphatase activity toward substrates and drug sensitivity.

Nygren PJ, Mehta S, Schweppe DK, Langeberg LK, Whiting JL, Weisbrod CR, Bruce JE, Zhang J, Veesler D, Scott JD.

Elife. 2017 Oct 2;6. pii: e30872. doi: 10.7554/eLife.30872.


Prognostic factors in patients with loco-regionally advanced gastric cancer.

Hultman B, Gunnarsson U, Nygren P, Sundbom M, Glimelius B, Mahteme H.

World J Surg Oncol. 2017 Sep 15;15(1):172. doi: 10.1186/s12957-017-1243-z.


Local protein kinase A action proceeds through intact holoenzymes.

Smith FD, Esseltine JL, Nygren PJ, Veesler D, Byrne DP, Vonderach M, Strashnov I, Eyers CE, Eyers PA, Langeberg LK, Scott JD.

Science. 2017 Jun 23;356(6344):1288-1293. doi: 10.1126/science.aaj1669.


U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.

Glimelius B, Melin B, Enblad G, Alafuzoff I, Beskow A, Ahlström H, Bill-Axelson A, Birgisson H, Björ O, Edqvist PH, Hansson T, Helleday T, Hellman P, Henriksson K, Hesselager G, Hultdin M, Häggman M, Höglund M, Jonsson H, Larsson C, Lindman H, Ljuslinder I, Mindus S, Nygren P, Pontén F, Riklund K, Rosenquist R, Sandin F, Schwenk JM, Stenling R, Stålberg K, Stålberg P, Sundström C, Thellenberg Karlsson C, Westermark B, Bergh A, Claesson-Welsh L, Palmqvist R, Sjöblom T.

Acta Oncol. 2018 Feb;57(2):187-194. doi: 10.1080/0284186X.2017.1337926. Epub 2017 Jun 20.


Affibody Molecules in Biotechnological and Medical Applications.

Ståhl S, Gräslund T, Eriksson Karlström A, Frejd FY, Nygren PÅ, Löfblom J.

Trends Biotechnol. 2017 Aug;35(8):691-712. doi: 10.1016/j.tibtech.2017.04.007. Epub 2017 May 14. Review.


The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation.

Blom K, Senkowski W, Jarvius M, Berglund M, Rubin J, Lenhammar L, Parrow V, Andersson C, Loskog A, Fryknäs M, Nygren P, Larsson R.

Immunopharmacol Immunotoxicol. 2017 Aug;39(4):199-210. doi: 10.1080/08923973.2017.1320671. Epub 2017 May 4.


Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity.

Karlsson H, Fryknäs M, Strese S, Gullbo J, Westman G, Bremberg U, Sjöblom T, Pandzic T, Larsson R, Nygren P.

Oncotarget. 2017 May 2;8(18):30217-30234. doi: 10.18632/oncotarget.16324.


Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis.

Blom K, Nygren P, Larsson R, Andersson CR.

SLAS Technol. 2017 Jun;22(3):306-314. doi: 10.1177/2472630316686297. Epub 2017 Jan 31.


Large-Scale Gene Expression Profiling Platform for Identification of Context-Dependent Drug Responses in Multicellular Tumor Spheroids.

Senkowski W, Jarvius M, Rubin J, Lengqvist J, Gustafsson MG, Nygren P, Kultima K, Larsson R, Fryknäs M.

Cell Chem Biol. 2016 Nov 17;23(11):1428-1438. doi: 10.1016/j.chembiol.2016.09.013. Epub 2016 Oct 27.


Iron chelators target both proliferating and quiescent cancer cells.

Fryknäs M, Zhang X, Bremberg U, Senkowski W, Olofsson MH, Brandt P, Persson I, D'Arcy P, Gullbo J, Nygren P, Schughart LK, Linder S, Larsson R.

Sci Rep. 2016 Dec 7;6:38343. doi: 10.1038/srep38343.


Regulation of the phosphatase PP2B by protein-protein interactions.

Nygren PJ, Scott JD.

Biochem Soc Trans. 2016 Oct 15;44(5):1313-1319. Review.


The BR domain of PsrP interacts with extracellular DNA to promote bacterial aggregation; structural insights into pneumococcal biofilm formation.

Schulte T, Mikaelsson C, Beaussart A, Kikhney A, Deshmukh M, Wolniak S, Pathak A, Ebel C, Löfling J, Fogolari F, Henriques-Normark B, Dufrêne YF, Svergun D, Nygren PÅ, Achour A.

Sci Rep. 2016 Sep 1;6:32371. doi: 10.1038/srep32371.


High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer.

Padhan N, Nordling TE, Sundström M, Åkerud P, Birgisson H, Nygren P, Nelander S, Claesson-Welsh L.

BMC Cancer. 2016 Aug 25;16(1):683. doi: 10.1186/s12885-016-2725-z.


Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life.

Stefansson M, Nygren P.

Acta Oncol. 2016 Sep - Oct;55(9-10):1227-1235. doi: 10.1080/0284186X.2016.1197420. Epub 2016 Aug 23.


Preclinical activity of melflufen (J1) in ovarian cancer.

Carlier C, Strese S, Viktorsson K, Velander E, Nygren P, Uustalu M, Juntti T, Lewensohn R, Larsson R, Spira J, De Vlieghere E, Ceelen WP, Gullbo J.

Oncotarget. 2016 Sep 13;7(37):59322-59335. doi: 10.18632/oncotarget.11163.


The Development of a Nurse-Led Internet-Based Learning and Self-care Program for Cancer Patients With Symptoms of Anxiety and Depression-A Part of U-CARE.

Hauffman A, Alfonsson S, Mattsson S, Forslund M, Bill-Axelson A, Nygren P, Johansson B.

Cancer Nurs. 2017 Sep/Oct;40(5):E9-E16. doi: 10.1097/NCC.0000000000000402.


Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy.

Månsson C, Brahmstaedt R, Nilsson A, Nygren P, Karlson BM.

Eur J Surg Oncol. 2016 Sep;42(9):1401-6. doi: 10.1016/j.ejso.2016.01.024. Epub 2016 Feb 10.


It's not as simple as it sounds: Problems and solutions in accessing and using administrative child welfare data for evaluating the impact of early childhood interventions.

Green BL, Ayoub C, Dym Bartlett J, Furrer C, Von Ende A, Chazan-Cohen R, Klevens J, Nygren P.

Child Youth Serv Rev. 2015 Oct;57:40-49.


AKAP150 participates in calcineurin/NFAT activation during the down-regulation of voltage-gated K(+) currents in ventricular myocytes following myocardial infarction.

Nieves-Cintrón M, Hirenallur-Shanthappa D, Nygren PJ, Hinke SA, Dell'Acqua ML, Langeberg LK, Navedo M, Santana LF, Scott JD.

Cell Signal. 2016 Jul;28(7):733-40. doi: 10.1016/j.cellsig.2015.12.015. Epub 2015 Dec 24.


First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.

Berglund Å, Ullén A, Lisyanskaya A, Orlov S, Hagberg H, Tholander B, Lewensohn R, Nygren P, Spira J, Harmenberg J, Jerling M, Alvfors C, Ringbom M, Nordström E, Söderlind K, Gullbo J.

Invest New Drugs. 2015 Dec;33(6):1232-41. doi: 10.1007/s10637-015-0299-2. Epub 2015 Nov 10.


In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index.

Kashif M, Andersson C, Hassan S, Karlsson H, Senkowski W, Fryknäs M, Nygren P, Larsson R, Gustafsson MG.

Sci Rep. 2015 Sep 22;5:14118. doi: 10.1038/srep14118.


Therapeutic strategies for anchored kinases and phosphatases: exploiting short linear motifs and intrinsic disorder.

Nygren PJ, Scott JD.

Front Pharmacol. 2015 Jul 28;6:158. doi: 10.3389/fphar.2015.00158. eCollection 2015. Review.


Inhibitory effects of H-Ras/Raf-1-binding affibody molecules on synovial cell function.

Shibasaki S, Karasaki M, Gräslund T, Nygren PÅ, Sano H, Iwasaki T.

AMB Express. 2014 Dec;4(1):82. doi: 10.1186/s13568-014-0082-3. Epub 2014 Nov 11.


Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy.

Blom K, Nygren P, Alvarsson J, Larsson R, Andersson CR.

J Lab Autom. 2016 Feb;21(1):178-87. doi: 10.1177/2211068215598117. Epub 2015 Aug 5.


The Aggregatibacter actinomycetemcomitans Cytolethal Distending Toxin Active Subunit CdtB Contains a Cholesterol Recognition Sequence Required for Toxin Binding and Subunit Internalization.

Boesze-Battaglia K, Walker LP, Zekavat A, Dlakić M, Scuron MD, Nygren P, Shenker BJ.

Infect Immun. 2015 Oct;83(10):4042-55. doi: 10.1128/IAI.00788-15. Epub 2015 Jul 27.

Supplemental Content

Loading ...
Support Center